Nuvation Bio Inc. (NUVB) climbed 8.43%, rising $0.63 to $8.10, following the publication of favorable Phase 2 clinical trial results for its drug safusidenib in patients with grade-2 IDH1-mutant glioma.
The data demonstrated promising safety and efficacy, raising hopes for a new treatment option in neuro-oncology.
Investors reacted to the news with heightened trading activity, sending volume well above average. The stock's 52-week range is approximately $4.20 - $9.45.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.